NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET
Company Participants
Kendra Sweeney - Vice President, Investor Relations and ESG
Chris Smith - Chief Executive Officer
Jeffrey Sherman - Chief Financial Officer
Warren Stone - Chief Commercial Officer
Kareem Saad - Head, Strategy and Transformation
Andrew Lukowiak - Chief Innovation Officer
Nate Montgomery - Vice President, Medical Services
Melody Harris - Chief Operations Officer and President, Informatics
Conference Call Participants
Andrew Brackman - William Blair
David Westenberg - Piper Sandler
Mike Matson - Needham & Company
Matthew Hewitt - Craig-Hallum Capital Group
Prashant Kota - Goldman Sachs
Mark Massaro - BTIG
Mason Carrico - Stephens, Inc.
John Kim - Bank of America
Andrew Cooper - Raymond James
Puneet Souda - SVB Leerink
Operator
Welcome to the NeoGenomics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Please note this call is being recorded and an audio replay will be available on the company's website.
I would now hand the call over to Kendra Sweeney, Vice President of Investor Relations. You may begin.
Kendra Sweeney
Thank you, Jenny. Good afternoon, everyone, and welcome to the NeoGenomics third quarter 2024 financial results call.
With me today to discuss the results are Chris Smith, Chief Executive Officer; and Jeff Sherman, Chief Financial Officer. Additional members of the management team are available for Q&A, including Warren Stone, Chief Commercial Officer; Melody Harris, Chief Operations Officer and President of Informatics; Andrew Lukowiak, Chief Innovation Officer; Dr. Nate Montgomery, Head of Medical; and Kareem Saad, Head of Strategy and Transformation.
This call is being simultaneously webcast. We'll be referring to a slide presentation that has been posted to the investors tab on our website at ir.neogenomics.com.
Starting on slide two. During this call, we will make forward-looking statements regarding our anticipated future performance. We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to our most recent forms 10-K, 10-Q, and 8-K we filed with the SEC to identify important risks and other factors that may cause our actual results to differ materially from the forward-looking statements. The forward-looking statements made during this call speak only as of the original date of the call, and we undertake no obligation to update or revise any of these statements.